Stockscreener 앱 받기
3.6837
0.77%
0.0337
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics Advances 212Pb Radioligand Therapy for Targeted Oncology with Regional Manufacturing and Theranostic Approach 1245 - Minichart
Perspective Therapeutics, Inc. (CATX) Shareholder/Analyst CallSlideshow (NYSE:CATX) 2026-05-04 - Seeking Alpha
Perspective Therapeutics (CATX) unveils 212Pb theranostic pipeline and manufacturing strategy - Stock Titan
Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field - Seeking Alpha
BlackRock stake in Perspective Therapeutics (CATX): 5.25M shares - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics to Provide Several Upcoming Corporate Updates - The Manila Times
Perspective Therapeutics, Inc. to Provide Corporate Updates and Financial Results in May 2026 - Quiver Quantitative
Perspective Therapeutics maps out May updates, Q1 results on May 11 - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perspective Therapeutics (CATX) and UnitedHealth (UNH) - The Globe and Mail
CATX (Perspective Therapeutics Inc.) slips 1.41% after reporting Q4 2025 EPS that misses analyst estimates by 40.3%.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
CATX Technical Analysis | Trend, Signals & Chart Patterns | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Centessa Pharmaceuticals (CNTA) and Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics reports interim trial results for NET therapy By Investing.com - Investing.com India
Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight - GlobeNewswire Inc.
CATX Reiterates by Wedbush -- Price Target Maintained at $11 - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Gap UpShould You Buy? - MarketBeat
[212Pb]VMT-α-NET Shows Promising Safety and Efficacy in Advanced Neuroendocrine Tumor Phase I/IIa Trial (Data Cutoff March 2026) - Minichart
Perspective Therapeutics (CATX) Updates Clinical Trial Results f - GuruFocus
Wedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX) - MarketBeat
Perspective Therapeutics reports interim trial results for NET therapy - Investing.com
Perspective Therapeutics Provides Updated Interim Results From Phase 1/2a Cancer Trial - marketscreener.com
Perspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting - The Manila Times
Perspective Therapeutics posts updated Phase 1/2a [212Pb]VMT-α-NET data showing 43% response in Cohort 2 - TradingView
[8-K] Perspective Therapeutics, Inc. Reports Material Event - Stock Titan
EBITDA per share of Perspective Therapeutics, Inc. – FWB:AAJ0 - TradingView
Perspective Therapeutics (NASDAQ: CATX) sets 2026 director, auditor and pay vote - Stock Titan
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Large Increase in Short Interest - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics Inc. R (AAJ0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
JPMorgan Chase & Co. Sells 311,710 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
CATX Stock Price, Quote & Chart | PERSPECTIVE THERAPEUTICS INC (NYSEARCA:CATX) - ChartMill
PERSPECTIVE THERAPEUTICS INC (CATX) Fundamental Analysis & Valuation - ChartMill
Perspective Therapeutics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Perspective Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Perspective Therapeutics Advances First-in-Class 212Pb Radiopharmaceuticals for Solid Tumor Oncology Treatment - Minichart
Perspective Therapeutics Highlights Progress in 212Pb Oncology Pipeline - TipRanks
Perspective Therapeutics updates corporate presentation, expects Phase 1/2 data across three programs in 2026 - TradingView — Track All Markets
Perspective Therapeutics (NYSE: CATX) spotlights 212Pb radiopharmaceutical cancer pipeline - Stock Titan
Revenue Check: Can Perspective Therapeutics Inc grow without dilution2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
CATX Rallies on Merger News - UBND thành phố Hải Phòng
Analyst Upgrade: Can Perspective Therapeutics Inc expand into new marketsRisk Management & Weekly Hot Stock Watchlists - baoquankhu1.vn
Aug Analyst Calls: What is the next catalyst for Perspective Therapeutics IncGlobal Markets & Advanced Technical Analysis Signals - baoquankhu1.vn
Perspective Therapeutics Q1 EPS Raised by HC Wainwright - MarketBeat
Investment Recap: What is the next catalyst for Perspective Therapeutics IncMarket Growth Report & Risk Controlled Daily Plans - baoquankhu1.vn
H.C. Wainwright raises Perspective Therapeutics price target to $13 By Investing.com - Investing.com South Africa
CATX: HC Wainwright & Co. Raises Price Target to $13, Maintains Buy Rating | CATX Stock News - GuruFocus
H.C. Wainwright raises Perspective Therapeutics price target to $13 - Investing.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Given New $13.00 Price Target at HC Wainwright - MarketBeat
0.76%
0.72%
자본화:
|
볼륨(24시간):